MediSense Co., Ltd. is a health-innovation company built on two programs: SilenEar, a non-invasive neuromodulation device for tinnitus, and NaCo·AI, a computational drug-discovery platform for orphan diseases and companion animal health.
A non-invasive neuromodulation and digital health device for tinnitus, combining personalized sound therapy with non-invasive stimulation.
Learn moreA computational drug-discovery platform that engineers clinically validated natural-product scaffolds into new chemical entities for orphan diseases and companion animal health.
Learn moreLead therapeutic device · non-invasive neuromodulation for tinnitus
SilenEar is a non-invasive neuromodulation and digital health device for tinnitus. It combines personalized sound therapy with non-invasive stimulation, with conservative physiological (HRV) monitoring built in as a safety control. MediSense has completed an FDA Pre-Submission (Q-Sub) and is pursuing a Class II, 510(k) pathway, with a feasibility study planned in Taiwan and a pivotal clinical study planned in the United States.
Computational drug discovery · discovery-stage (preclinical)
Most drug discovery starts from blank chemistry. We don't. Our starting compounds come from pharmacopoeias with decades to centuries of documented clinical use — with published pharmacokinetic data, known safety profiles, and real biological signals.
Rather than screening at random, the platform uses each compound's structure to guide targeted molecular improvements — designing better candidates, not just filtering existing ones.
Computational predictions are checked against real-world laboratory results, and each round of experimental feedback sharpens the platform's accuracy over time.
We operate a dual-track strategy: orphan disease assets targeting Priority Review Voucher (PRV) and Orphan Drug Designation (ODD) pathways, alongside companion animal licensing as a nearer-term commercial track. Both tracks run on the same NaCo·AI computational foundation.
MediSense Co., Ltd.
Taichung, Taiwan